Viking Therapeutics, Inc. - COMMON STOCK (VKTX) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2015 to Q4 2025

Type / Class
Equity / COMMON STOCK
Symbol
VKTX on Nasdaq
Shares outstanding
113,177,462
Price per share
$35.18
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
71,246,268
Total reported value
$1,872,344,324
% of total 13F portfolios
0%
Share change
-4,913,247
Value change
-$130,051,164
Number of holders
363
Price from insider filings
$35.18
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Viking Therapeutics, Inc. - COMMON STOCK (VKTX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 5.1% -40% $151,689,488 -$105,010,859 5,772,051 -41% FMR LLC 30 Sep 2025
BlackRock, Inc. 4.5% -16% $140,580,417 -$23,501,200 5,031,511 -14% BlackRock, Inc. 31 Mar 2025

As of 30 Sep 2025, 363 institutional investors reported holding 71,246,268 shares of Viking Therapeutics, Inc. - COMMON STOCK (VKTX). This represents 63% of the company’s total 113,177,462 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Viking Therapeutics, Inc. - COMMON STOCK (VKTX) together control 47% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
VANGUARD GROUP INC 8.8% 9,999,107 -1.6% 0% $262,776,531
FMR LLC 5.1% 5,790,051 -41% 0.01% $152,162,529
BlackRock, Inc. 4.9% 5,596,166 +2.9% 0% $147,067,246
STATE STREET CORP 4% 4,513,832 +20% 0% $118,623,505
MORGAN STANLEY 3.3% 3,729,117 +15% 0.01% $98,001,218
JPMORGAN CHASE & CO 2.3% 2,577,087 -2.3% 0% $67,725,865
SUSQUEHANNA INTERNATIONAL GROUP, LLP 1.9% 2,099,564 +1.6% 0.08% $55,176,542
AMERIPRISE FINANCIAL INC 1.8% 2,092,840 +42% 0.01% $54,999,836
TWO SIGMA INVESTMENTS, LP 1.8% 2,085,487 +59% 0.08% $54,806,598
CITADEL ADVISORS LLC 1.7% 1,898,342 +117% 0.04% $49,888,428
GEODE CAPITAL MANAGEMENT, LLC 1.4% 1,608,606 -16% 0% $42,284,245
TWO SIGMA ADVISERS, LP 1.4% 1,555,128 +42% 0.08% $40,868,764
UBS Group AG 1.2% 1,342,308 +41% 0.01% $35,275,855
Pictet Asset Management Holding SA 1.1% 1,196,305 -38% 0.03% $31,438,895
RAYMOND JAMES FINANCIAL INC 0.84% 954,272 +16% 0.01% $25,078,269
TANG CAPITAL MANAGEMENT LLC 0.77% 870,000 +135% 0.88% $22,863,600
JANE STREET GROUP, LLC 0.7% 793,806 +8.4% 0.02% $20,861,222
BRAIDWELL LP 0.67% 759,455 -47% 0.59% $19,958,477
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.62% 697,708 -4.1% 0% $18,335,766
ROYAL BANK OF CANADA 0.57% 648,295 +6% 0% $17,037,000
BANK OF AMERICA CORP /DE/ 0.51% 578,268 +10% 0% $15,196,884
NORTHERN TRUST CORP 0.49% 557,269 +2.6% 0% $14,645,029
Connor, Clark & Lunn Investment Management Ltd. 0.48% 544,201 +22% 0.05% $14,301,602
PRINCIPAL FINANCIAL GROUP INC 0.45% 514,002 -9% 0.01% $13,507,972
BlackBarn Capital Partners LP 0.44% 500,000 +43% 4.3% $13,140,000

Institutional Holders of Viking Therapeutics, Inc. - COMMON STOCK (VKTX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 630,667 $21,602,375 +$3,002,548 $35.18 52
2025 Q3 71,246,268 $1,872,344,324 -$130,051,164 $26.28 363
2025 Q2 76,160,666 $2,018,412,050 +$15,581,298 $26.50 386
2025 Q1 76,178,049 $1,840,349,819 -$233,469,532 $24.15 365
2024 Q4 82,015,393 $3,300,204,748 -$139,093,256 $40.24 405
2024 Q3 82,930,091 $5,250,281,341 +$233,179,536 $63.31 418
2024 Q2 80,417,324 $4,262,902,509 -$169,985,696 $53.01 383
2024 Q1 80,009,652 $6,559,940,568 +$370,099,401 $82.00 365
2023 Q4 76,419,206 $1,422,250,248 +$18,477,372 $18.61 193
2023 Q3 77,149,919 $854,043,342 +$8,950,047 $11.07 176
2023 Q2 74,791,312 $1,212,232,718 +$127,119,937 $16.21 192
2023 Q1 66,472,048 $1,107,025,988 +$548,273,938 $16.65 183
2022 Q4 34,003,932 $319,613,212 +$76,425,883 $9.40 126
2022 Q3 26,578,143 $72,293,762 -$1,008,538 $2.72 95
2022 Q2 26,701,115 $77,182,300 -$11,574,558 $2.89 97
2022 Q1 31,036,457 $93,177,398 -$16,601,086 $3.00 131
2021 Q4 36,199,999 $166,471,159 -$8,903,915 $4.60 133
2021 Q3 37,764,404 $237,662,655 -$338,194 $6.28 125
2021 Q2 37,867,341 $226,858,479 -$19,626,288 $5.99 133
2021 Q1 41,005,365 $259,319,860 +$20,962,700 $6.32 137
2020 Q4 37,734,744 $212,602,882 -$11,096,629 $5.63 136
2020 Q3 39,564,196 $230,268,043 -$4,355,775 $5.82 139
2020 Q2 40,230,477 $290,007,852 +$8,150,488 $7.21 133
2020 Q1 39,356,943 $184,161,493 -$8,373,431 $4.68 130
2019 Q4 39,771,461 $318,974,059 -$5,272,426 $8.02 134
2019 Q3 40,703,230 $280,039,135 -$33,395,341 $6.88 139
2019 Q2 45,087,675 $374,231,879 -$7,341,449 $8.30 150
2019 Q1 45,718,634 $454,329,676 -$4,966,661 $9.94 158
2018 Q4 46,936,233 $359,030,721 -$11,223,062 $7.65 159
2018 Q3 43,213,947 $752,787,195 +$280,535,030 $17.42 146
2018 Q2 31,601,829 $299,901,220 +$126,057,321 $9.49 115
2018 Q1 20,905,622 $91,354,000 +$50,569,356 $4.37 62
2017 Q4 9,329,591 $37,876,000 +$30,074,098 $4.06 32
2017 Q3 2,021,286 $3,851,000 +$1,491,357 $1.91 16
2017 Q2 1,568,425 $1,692,000 +$856,257 $1.08 11
2017 Q1 769,601 $1,124,000 +$226,915 $1.46 10
2016 Q4 636,030 $757,000 -$869,302 $1.19 11
2016 Q3 1,209,905 $1,701,000 +$495,636 $1.41 13
2016 Q2 860,090 $1,083,000 +$1,026,020 $1.26 12
2016 Q1 44,443 $65,000 -$25,998 $1.53 6
2015 Q4 41,278 $140,000 -$14,614 $3.36 5
2015 Q3 43,175 $252,000 -$77,596 $5.83 6
2015 Q2 54,005 $384,000 +$384,000 $7.10 5